Barclays Reiterates an 'Overweight' on St. Jude Medical (STJ); No New Info in FDA's Riata Classification
Tweet Send to a FriendGet Alerts STJ Hot Sheet
Price: $45.15 -0.04%
Rating Summary:
10 Buy, 10 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
10 Buy, 10 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade STJ Now!
Barclays reiterates an 'Overweight' on St. Jude Medical (NYSE: STJ) price target of $51.00.
Barclays analyst says, "In response to the FDA's classification, HRS's former president noted that "no blanket statement can be made about clinical recommendations until more data is collected" and that "physicians should follow standard practice of care to manage patients with Riata silicone leads." Over the next few weeks there will be two public meetings scheduled to discuss Riata and associated clinical recommendations: a webinar sponsored by HRS on 12/21 (5-6:30 PM and available to the public for a fee), and a summit sponsored by the Minneapolis Heart Institute on 1/20/12 (9 AM - 5:30 PM and restricted to physicians/health professional who treat ICD patients). Net/net, we think the overall risk from concerns over Riata is manageable. At ~9.4x 2012 EPS, we view the shares of STJ as undervalued and reiterate our rating."
For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.
Shares of St. Jude Medical closed at $33.60 yesterday, with a 52 week range of $33.52-$54.12.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Barclays analyst says, "In response to the FDA's classification, HRS's former president noted that "no blanket statement can be made about clinical recommendations until more data is collected" and that "physicians should follow standard practice of care to manage patients with Riata silicone leads." Over the next few weeks there will be two public meetings scheduled to discuss Riata and associated clinical recommendations: a webinar sponsored by HRS on 12/21 (5-6:30 PM and available to the public for a fee), and a summit sponsored by the Minneapolis Heart Institute on 1/20/12 (9 AM - 5:30 PM and restricted to physicians/health professional who treat ICD patients). Net/net, we think the overall risk from concerns over Riata is manageable. At ~9.4x 2012 EPS, we view the shares of STJ as undervalued and reiterate our rating."
For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.
Shares of St. Jude Medical closed at $33.60 yesterday, with a 52 week range of $33.52-$54.12.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- St. Jude Medical (STJ) Issues Encouraging Update for EnligHTN™ Multi-Electrode Renal Denervation System Following One Year
- Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold
- Hewlett-Packard (HPQ) Q2 Performance Wins Praise on Wall Street; Jefferies Raises to Hold
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Barclays
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
